Aktie A2PHD4 IMMUNIC, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Immunic, Inc.

Aktien

A2PHD4

US4525EP1011

IMUX

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 21.05.2024 		% 5 Tage % 1. Jan.
1,27 USD -1,55 % Intraday Chart für Immunic, Inc. -0,78 % -15,33 %
08.05. Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024
08.05. Immunic, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day
Immunic chief medical officer discusses promising treatments to mark World IBD Day
Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day
Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones
Immunic : Q1 2024 News Release
Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Immunic: Q1 Earnings Snapshot
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
Immunic to Participate in Investor and Scientific Conferences in May
Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Announces Publication of Extended Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology Neuroimmunology and Neuroinflammation
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
Immunic CEO Dr Daniel Vitt marks International Day of Immunology with discussion on its crucial role
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
Immunic Gets US Patent Notice of Allowance For Specific Polymorph of Vidofludimus Calcium
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PHD4 Aktie
  4. Nachrichten Immunic, Inc.
  5. Andere Sprachen